ArticleEuropean heart journal. Digital health2026
Cardio amyloid-artificial intelligence: advanced multi-modal screening for transthyretin cardiac amyloidosis in severe aortic stenosis patients.
Article in European heart journal. Digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial Intelligence for the Diagnosis of Transthyretin Amyloid Cardiomyopathy: A Systematic Review of Machine Learning Application.Cardiology research and practice · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Early detection is important given the availability of new disease-modifying therapies and the high prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM) among patients with aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR). We developed a multi-modal artificial intelligence (AI) model for early detection of ATTR-CM using chest computed tomography (CT), echocardiography, and electrocardiography. This approach may provide a scalable strategy for preclinical monitoring. Methods and results: This retrospective study included patients who underwent technetium-99m-pyrophosphate (PYP) scintigraphy at two academic medical centres: Columbia University Irving Medical Center and Weill Cornell Medicine. ATTR-CM status was determined using a composite reference standard incorporating PYP scan interpretation, laboratory tests, and endomyocardial biopsy results when available. The diagnostic performance of the model was measured by the area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, and predictive values at various thresholds. Among 816 patients (median age 79.0 years, 61.2% male), 127 (15.6%) had confirmed ATTR-CM. Patients with ATTR-CM were older, more often male, and had characteristic echocardiographic features, including increased wall thickness and reduced ejection fraction. In the independent TAVR test cohort, the multi-modal AI model achieved an AUROC of 0.85 [95% confidence interval (CI): 0.74-0.93], significantly outperforming single-modality approaches in our data. At the optimal threshold, the model demonstrated 73.3% sensitivity, 82.9% specificity, and 96% negative predictive value. Conclusion: A multi-modal AI approach using routinely acquired chest CT, echocardiography, and electrocardiography data can enable screening for ATTR-CM in TAVR patients, potentially facilitating earlier diagnosis and treatment initiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.